ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.